Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades

ABSTRACT The epitopes of the V3 domain of the human immunodeficiency virus type 1 (HIV-1) gp120 glycoprotein have complex structures consisting of linear and conformational antigenic determinants. Anti-V3 antibodies (Abs) recognize both types of elements, but Abs which preferentially react to the conformational aspect of the epitopes may have more potent neutralizing activity against HIV-1, as recently suggested. To test this hypothesis, human anti-V3 monoclonal Abs (MAbs) were selected using a V3 fusion protein (V3-FP) which retains the conformation of the third variable region. The V3-FP consists of the V3JR-CSF sequence inserted into a truncated form of murine leukemia virus gp70. Six human MAbs which recognize epitopes at the crown of the V3 loop were selected with the V3-FP. They were found to react more strongly with molecules displaying conformationally intact V3 than with linear V3 peptides. In a virus capture assay, these MAbs showed cross-clade binding to native, intact virions of clades A, B, C, D, and F. No binding was found to isolates from subtype E. The neutralizing activity of MAbs against primary isolates was determined in three assays: the GHOST cell assay, a phytohemagglutinin-stimulated peripheral blood mononuclear cell assay, and a luciferase assay. While these new MAbs displayed various degrees of activity, the pattern of cross-clade neutralization of clades A, B, and F was most pronounced. The neutralization of clades C and D viruses was weak and sporadic, and neutralization of clade E by these MAbs was not detected. Analysis by linear regression showed a highly significant correlation (P < 0.0001) between the strength of binding of these anti-V3 MAbs to intact virions and the percent neutralization. These studies demonstrate that human MAbs to conformation-sensitive epitopes of V3 display cross-clade reactivity in both binding to native, intact virions and neutralization of primary isolates.

[1]  S. Zolla-Pazner,et al.  Mapping of Epitopes Exposed on Intact Human Immunodeficiency Virus Type 1 (HIV-1) Virions: a New Strategy for Studying the Immunologic Relatedness of HIV-1 , 1998, Journal of Virology.

[2]  S. Zolla-Pazner,et al.  Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M , 2000, Journal of Virology.

[3]  S. Zolla-Pazner,et al.  Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. , 1994, Virology.

[4]  K. Lam,et al.  Construction and testing of mouse--human heteromyelomas for human monoclonal antibody production. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[5]  I. Wilson,et al.  Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs. , 1999, Structure.

[6]  P. Kaleebu,et al.  Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization , 1996, Journal of virology.

[7]  E. Tramont,et al.  The human immunodeficiency virus. , 1991, Dermatologic clinics.

[8]  C. Cheng‐Mayer,et al.  Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.

[9]  S. Zolla-Pazner,et al.  Immunotyping of Human Immunodeficiency Virus Type 1 (HIV): an Approach to Immunologic Classification of HIV , 1999, Journal of Virology.

[10]  S. Zolla-Pazner,et al.  HIV Type 1 Group M Clades Infecting Subjects From Rural Villages in Equatorial Rain Forests of Cameroon , 2002, Journal of acquired immune deficiency syndromes.

[11]  J. Hansen,et al.  Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. , 1993, The Journal of general virology.

[12]  A J Langlois,et al.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Birx,et al.  Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. , 1995, AIDS research and human retroviruses.

[14]  L. Arthur,et al.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Simmonds,et al.  Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. , 1998, The Journal of general virology.

[16]  J. Hansen,et al.  Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120. , 1992, The Journal of general virology.

[17]  B. McMahon,et al.  Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study. , 1997, The Journal of infectious diseases.

[18]  S. Zolla-Pazner,et al.  Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. , 1997, International immunology.

[19]  S. Zolla-Pazner,et al.  Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins. , 2000, Virology.

[20]  A. Trkola,et al.  A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B , 1995, Journal of virology.

[21]  J. Mascola,et al.  A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. , 1998, AIDS research and human retroviruses.

[22]  R L Stanfield,et al.  Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Lei Jin,et al.  Induction and Characterization of Neutralizing Antibodies against a Human Immunodeficiency Virus Type 1 Primary Isolate , 2001, Journal of Virology.

[24]  J. Mascola.  Neutralization of HIV-1 Infection of Human Peripheral Blood Mononuclear Cells (PBMC) : Infectivity Reduction Method. , 1999, Methods in molecular medicine.

[25]  S. Zolla-Pazner,et al.  Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. , 1993, Journal of immunology.

[26]  S. Zolla-Pazner,et al.  Generation of Neutralizing Human Monoclonal Antibodies against Parvovirus B19 Proteins , 1999, Journal of Virology.

[27]  R. Gallo,et al.  Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees , 1990, Journal of virology.

[28]  A J Langlois,et al.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[30]  L. van der Hoek,et al.  Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. , 1994, AIDS research and human retroviruses.

[31]  S. Zolla-Pazner,et al.  Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor , 1997, Journal of virology.

[32]  I. Wilson,et al.  Crystal structure of the principal neutralization site of HIV-1. , 1994, Science.

[33]  S. Zolla-Pazner,et al.  Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Mascola.  Neutralization of HIV-1 Infection of Human Peripheral Blood Mononuclear Cells (PBMC) : Antibody Dilution Method. , 1999, Methods in molecular medicine.

[35]  S. Zolla-Pazner,et al.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies , 1991, Journal of virology.

[36]  Robert A. Bloodgood,et al.  Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation. , 1985, Journal of immunological methods.

[37]  L. Sawyer,et al.  Defining Surrogate Serologic Tests with Respect to Predicting Protective Vaccine Efficacy: Poliovirus Vaccination , 1995, Annals of the New York Academy of Sciences.

[38]  A. Trkola,et al.  Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization. , 1998, AIDS research and human retroviruses.

[39]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[40]  E. Hunter,et al.  V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. , 1992, Virology.

[41]  A. Pinter,et al.  Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains , 1994, Journal of virology.

[42]  S. Zolla-Pazner,et al.  A Human Immunodeficiency Virus Prime-Boost Immunization Regimen in Humans Induces Antibodies That Show Interclade Cross-Reactivity and Neutralize Several X4-, R5-, and Dualtropic Clade B and C Primary Isolates , 2000, Journal of Virology.

[43]  B. Cullen,et al.  Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. , 1991, Science.

[44]  Susan Zolla-Pazner,et al.  A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex , 2000, Journal of Virology.

[45]  H. Liao,et al.  Vaccine-Elicited V3 Loop-Specific Antibodies in Rhesus Monkeys and Control of a Simian-Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate Envelope , 2001, Journal of Virology.

[46]  B. Meyer,et al.  The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain , 1997, Journal of virology.

[47]  R K Craig,et al.  Methods in molecular medicine. , 1987, British medical journal.

[48]  P. Berman,et al.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization , 1994, Journal of virology.

[49]  S. Zolla-Pazner,et al.  Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. , 1997, Journal of immunology.

[50]  J. Nielsen,et al.  Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. , 1996, Virology.

[51]  R. Andino,et al.  Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses , 1994, Journal of virology.

[52]  S. Zolla-Pazner,et al.  Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies , 1994, Journal of virology.

[53]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[54]  S. Zolla-Pazner,et al.  Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage , 1998, Journal of Virology.

[55]  A. Pinter,et al.  V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.

[56]  al. et,et al.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications , 1991, Science.

[57]  Ying Sun,et al.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.

[58]  H. Dyson,et al.  Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. , 1997, Journal of molecular biology.

[59]  Q. Sattentau,et al.  Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins , 1998, Journal of Virology.

[60]  C. Debouck,et al.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Rina Levy,et al.  A cis proline turn linking two β-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide , 1999, Nature Structural Biology.

[62]  B. McMahon,et al.  Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results. , 1991, Archives of internal medicine.

[63]  J. Goudsmit,et al.  Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies , 1995, Journal of virology.

[64]  L. Pearl,et al.  Characterization of HIV‐1 neutralization escape mutants , 1989, AIDS.

[65]  S. Zolla-Pazner,et al.  Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D , 1994, Journal of virology.

[66]  S. Zolla-Pazner,et al.  Immunoreactivity of Intact Virions of Human Immunodeficiency Virus Type 1 (HIV-1) Reveals the Existence of Fewer HIV-1 Immunotypes than Genotypes , 2000, Journal of Virology.

[67]  J. Gatewood,et al.  Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[68]  H. Fleury,et al.  Study of the V3 Loop as a Target Epitope for Antibodies Involved in the Neutralization of Primary Isolates versus T-Cell-Line-Adapted Strains of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[69]  J. Mascola,et al.  Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. , 1996, AIDS research and human retroviruses.